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ORIGINAL RESEARCH • THORACIC IMAGING
In patients with chronic obstructive pulmonary disease (COPD), irreversible airflow obstruction related to pa-
renchymal destruction, airway remodeling, and luminal 
obstruction (1) drives debilitating symptoms, poor quality 
of life, and premature death. While forced expiratory vol-
ume in 1 second (FEV1) remains a key clinical and diag-
nostic measurement of COPD, it cannot provide regional 
information, nor can it be used to adequately discriminate 
between patients with different underlying diseases, such as 
airspace enlargement and small airways disease, that mani-
fest differently in individual patients.
To address some of the limitations of spirom-
etry measurements, thoracic x-ray CT has yielded 
quantitative airway (2) and parenchyma (3) informa-
tion, as well as indirect information related to small air-
ways disease generated using parametric response maps 
(4–6). Pulmonary CT has been used widely in studies 
such as the Genetic Epidemiology of Chronic Obstruc-
tive Pulmonary Disease, or COPDGene (7), Subpopu-
lations and Intermediate Outcome Measures in COPD, 
or SPIROMICS (8), Multi-Ethnic Study of Atheroscle-
rosis, or MESA (9), Canadian Cohort Obstructive Lung 
Disease, or CANCold (10), and Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate End-
points, or ECLIPSE (11). CT parametric response maps 
are used to quantify COPD severity (4,12), monitor 
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Background: Pulmonary imaging of chronic obstructive pulmonary disease (COPD) has focused on CT or MRI measurements, but 
these have not been evaluated in combination.
Purpose: To generate multiparametric response map (mPRM) measurements in ex-smokers with or without COPD by using vol-
ume-matched CT and hyperpolarized helium 3 (3He) MRI.
Materials and Methods: In this prospective study (https://clinicaltrials.gov, NCT02279329), participants underwent MRI and CT 
and completed pulmonary function tests, questionnaires, and the 6-minute walk test between December 2010 and January 2019. 
Disease status was determined by using Global initiative for chronic Obstructive Lung Disease (GOLD) criteria. The mPRM voxel 
values were generated by using co-registered MRI and CT labels. Kruskal-Wallis and Bonferroni tests were used to determine differ-
ences across disease severity, and correlations were determined by using Spearman coefficients.
Results: A total of 175 ex-smokers (mean age, 69 years 6 9 [standard deviation], 108 men) with or without COPD were evaluated. 
Ex-smokers without COPD had a larger fraction of normal mPRM voxels (60% vs 37%, 20%, and 7% for GOLD I, II, and III/
IV disease, respectively; all P  .001) and a smaller fraction of abnormal voxels, including small airways disease (normal CT, not 
ventilated: 5% vs 6% [not significant], 11%, and 19% [P  .001 for both] for GOLD I, II, and III/IV disease, respectively) and 
mild emphysema (normal CT, abnormal apparent diffusion coefficient [ADC]: 33% vs 54%, 56%, and 54% for GOLD I, II, and 
III/IV disease respectively; all P  .001). Normal mPRM measurements were positively correlated with forced expiratory volume 
in 1 second (FEV1) (r = 0.65, P , .001), the FEV1-to–forced vital capacity ratio (r = 0.81, P , .001), and diffusing capacity (r = 
0.75, P , .001) and were negatively correlated with worse quality of life (r = 20.48, P , .001). Abnormal mPRM measurements 
of small airways disease (normal CT, not ventilated) and mild emphysema (normal CT, abnormal ADC) were negatively correlated 
with FEV1 (r = 20.65 and 20.42, respectively; P , .001) and diffusing capacity (r = 20.53 and 20.60, respectively; P , .001) 
and were positively correlated with worse quality of life (r = 0.45 and r = 0.33, respectively; P , .001), both of which were present 
in ex-smokers without COPD.
Conclusion: Multiparametric response maps revealed two abnormal structure-function results related to emphysema and small air-
ways disease, both of which were unexpectedly present in ex-smokers with normal spirometry and CT findings.
© RSNA, 2020
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COPD progression (13,14), and predict survival after trans-
plantation (6).
Hyperpolarized noble gas MRI also has been used to measure 
regional lung ventilation (15) and airspace enlargement (16,17) 
in patients with COPD. MRI ventilation heterogeneity is quan-
tified by using ventilation defect percentage, which is related to 
COPD severity and exacerbation (18). Hyperpolarized helium 
3 (3He) MRI apparent diffusion coefficients (ADCs) may also 
be used in patients with COPD to estimate terminal airspace 
enlargement (17), and such measurements have been histologi-
cally validated (19).
The Thoracic Imaging Network of Canada (TINCan) (20) 
study performed volume-matched CT and MRI in ex-smokers 
with or without COPD in whom spatial correlations between 
MRI ventilation defects and nonenhanced low-dose CT mea-
surements of emphysema and small airways disease were re-
ported (18). CT parametric response map analysis in TINCan 
participants also revealed spatial correlations between parametric 
response map measurements of emphysema and gas trapping 
with MRI values (21). In addition, in the TINCan study, in a 
small group of at-risk ex-smokers without CT evidence of em-
physema and with modestly abnormal diffusing capacity, there 
was abnormal MRI ADC, profound exercise limitation, and di-
minished quality of life (22). Given the complementary nature 
of pulmonary CT and hyperpolarized gas MRI, we postulated 
that combining the information obtained with these two mo-
dalities would yield new measures of lung abnormality not seen 
when using CT or MRI alone. On the basis of these findings, 
we hypothesized that by combining MRI and CT measure-
ments using a multiparametric approach, phenotypes would be 
observed that cannot be detected using CT or MRI alone. The 
purpose of this study was to generate multiparametric response 
map (mPRM) measurements in ex-smokers with or without 
COPD using sequentially acquired volume-matched CT and 
hyperpolarized 3He MRI measurements.
Materials and Methods
Study Participants and Design
We evaluated ex-smokers with or without COPD who pro-
vided written informed consent to participate in a research 
ethics board–approved and Health Insurance Portability 
and Accountability Act–compliant registered study (https://
clinicaltrials.gov, NCT02279329). Participants were recruited 
from local tertiary care clinics and through advertisements as a 
convenience sample. Patients were included in the study if they 
were men or women aged 45–90 years with a clinical diagnosis 
of COPD or a smoking history of more than 10 pack-years who 
were in stable health and were ambulatory. Exclusion criteria 
included contraindications to MRI, missing complete CT and 
MRI data sets, or diagnosis of bronchiectasis only (Fig 1). The 
study was prospectively planned and performed from Decem-
ber 2010 to January 2019; participants underwent one 2-hour 
visit and completed spirometry, plethysmography, quality-of-
life questionnaires, exercise capacity tests, and MRI and CT 
examinations, as previously described (20). Evaluations were 
performed 20 minutes after administration of four 100-µg 
doses of novo-salbutamol hydrofluoroalkane via a metered-
dose inhaler (Teva Novopharm, Toronto, Ontario, Canada) 
through a spacer (AeroChamber Plus; Trudell Medical Interna-
tional, London, Ontario, Canada). Participants in the TINCan 
study have been previously described (18,22–26). These prior 
articles dealt with cross-sectional and longitudinal analyses of 
CT and MRI data and their relationships with quality of life, 
exacerbations, and exercise capacity, whereas in this article we 
report on the development of an mPRM approach and apply 
this to 175 TINCan participants who had the complete image 
data sets required for analysis. Data generated during this study 
are available from the corresponding author, and the mPRM 
method we developed is available online (www.imaging.robarts.
ca/parraga/).
Pulmonary Function and Quality-of-Life Tests
Spirometry and plethysmography were performed and diffus-
ing capacity of the lung for carbon monoxide (DLco ) was mea-
sured and evaluated according to the American Thoracic Soci-
ety and European Respiratory Society guidelines (27–29) using 
a body plethysmograph (MedGraphics Elite Series; MGC Di-
agnostic, St Paul, Minn) with an attached gas analyzer. The St. 
George’s Respiratory Questionnaire (SGRQ) was administered 
(30), and a 6-minute walk test was performed (31).
MRI Examination
All MRI examinations were performed using previously de-
scribed methods (20). Briefly, anatomic proton (1H), hyper-
polarized 3He static ventilation, and diffusion-weighted MRI 
were performed with the patient in the supine position in a 
3.0-T Discovery MR750 system (GE Healthcare, Milwaukee, 
Wis) with broadband imaging capabilities. The 1H MRI exam-
ination was performed using a fast spoiled gradient-recalled-
Abbreviations
ADC = apparent diffusion coefficient, COPD = chronic obstructive 
pulmonary disease, DLco = diffusing capacity of the lung for carbon 
monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced 
vital capacity, GOLD = Global initiative for chronic Obstructive Lung 
Disease, mPRM = multiparametric response map, SGRQ = St George’s 
Respiratory Questionnaire, TINCan = Thoracic Imaging Network of 
Canada
Summary
Multiparametric response maps derived from CT and hyperpolarized 
helium 3 MRI revealed emphysema and small airways disease not 
otherwise identified with CT or MRI alone.
Key Results
 n Combined CT and MRI multiparametric response maps 
(mPRMs) reflected chronic obstructive pulmonary disease 
(COPD) severity.
 n The fraction of lung occupied by normal mPRM voxels was 60% 
in ex-smokers without and 7% in those with Global initiative for 
chronic Obstructive Lung Disease III/IV (severe to very severe) 
COPD (P , .001).
 n Ex-smokers without COPD had patterns of subclinical emphysema 
(normal CT and ventilation with abnormal apparent diffusion coef-
ficients) and small airways disease (normal CT but not ventilated).
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ADC images were co-registered using intensity-based rigid reg-
istration. Image analysis specifics are provided in Appendix E1 
(online).
Development of mPRMs
Once all the images were co-registered, voxels within the pro-
ton thoracic cavity were labeled to generate mPRMs. These 
labels were generated based on ventilation, ADC values, and 
CT density histogram threshold values, as shown in Figure 2. 
The CT threshold of 2950 HU was used as a well-established 
and validated measure of emphysema in the lungs (3), whereas 
the ADC threshold of 0.30 cm2/sec was based on experimen-
tally acquired ADC values reported in a group of elderly par-
ticipants who had never smoked. The threshold we used was 
equal to 1 standard deviation of the mean of this group, as a 
conservative estimate. ADC values for this group of partici-
pants who had never smoked were previously reported (33). 
Although CT was performed at functional residual capacity 
plus 1 L, this lung volume is roughly 80%–90% of total lung 
capacity in patients with COPD, especially when lying su-
pine in the scanner; moreover, Madani and colleagues (34) 
also previously reported that such differences related to lung 
volume are within a few percentage points for relative area of 
the lung of less than 2950 HU values and that these are un-
likely to be clinically relevant. mPRMs were evaluated by an 
observer (J.L.M.). Figure 3 shows the generation of mPRM 
values and the five resultant mPRM voxel classifications: (a) 
normal (green); (b) ventilated, CT greater than or equal to 
2950 HU, abnormal ADC (yellow); (c) ventilated, CT em-
physema, abnormal ADC (orange); (d) not ventilated, CT 
greater than or equal to 2950 HU, no ADC (red); and (e) 
not ventilated, CT emphysema, no ADC (burgundy). ADC 
values reflect gas displacement but only in ventilated regions 
of the lung. Because CT and MRI scans were acquired at 
the same lung volume, the potential for co-registration er-
rors is low, but errors are not impossible. Hence, voxels la-
beled ventilated, CT emphysema, normal ADC were classified 
as registration errors because of the high sensitivity of MRI to 
emphysema, which suggests that normal ADC and CT em-
physema are unlikely in the same voxel, although this finding 
may also stem from partial volume averaging.
Statistical Analyses
Statistical tests were performed using statistical software (SPSS 
Statistics 25.0; SPSS, Armonk, NY). A Shapiro-Wilk test was 
used to determine normality of the data. Kruskal-Wallis tests 
with post hoc Dunn-Bonferroni correction were used to de-
termine differences between groups for mPRM voxel distri-
butions. Spearman correlation coefficients with a Bonferroni 
correction were determined for mPRM voxel distributions, 
pulmonary function, and quality-of-life test measurements. 
Since each clinical measurement was correlated multiple times 
with every mPRM classification measurement, a Bonferroni 
correction of six was multiplied to the original P values, and 
the adjusted P values were compared for significance. All re-
sults were considered significant when the probability of mak-
ing a type I error was less than 5% (P , .05).
echo sequence (repetition time msec/echo time msec, 4.7/1.2; 
flip angle, 30°) with a whole-body radiofrequency coil during 
breath holding after inhalation of 1.0 L of nitrogen (N2).
The 3He polarization was performed to 30%–40% polariza-
tion, and all 3He MRI examinations were performed using a 
single-channel rigid elliptical transmit-receive chest coil (RAPID 
Biomedical, Wuerzburg, Germany) during a breath hold of 1.0 
L of diluted hyperpolarized gas. The 3He static ventilation was 
performed using a fast spoiled gradient-recalled-echo sequence 
(4.3/1.4; flip angle, 7°) while diffusion-weighted 3He was per-
formed with a fast spoiled gradient-recalled-echo sequence 
(7.6/3.7; flip angle, 8°) with and without diffusion sensitization 
with a b value of 1.6 sec/cm2. A detailed description of the MRI 
acquisition parameters is provided in Appendix E1 (online).
CT Examination
Within 30 minutes of MRI, CT was performed with the pa-
tient in the supine position in a 64-slice Lightspeed VCT scan-
ner (GE Healthcare) during a breath hold after inhalation of 
1.0 L of N2 from functional residual capacity using the fol-
lowing parameters: 64 3 0.625 mm collimation, 120 kVp, 
100-mA effective current, 500-msec rotation time, and 1.0 
pitch (22). Specific CT acquisition parameters are provided 
in Appendix E1 (online). Total effective dose was estimated as 
1.8 mSv using the ImPACT CT patient dosimetry calculator 
(based on Health Protection Agency [UK] NRBP-SR250).
Image Analysis
MRI and CT image segmentations were performed by an ob-
server (J.L.M., 1.5 years of experience). The 3He and proton 
(1H) MRI scans were semiautomatically segmented and co-
registered using in-house software (21). Diffusion-weighted 
images were automatically processed to generate lung ADC 
images (21). CT images were segmented using Pulmonary 
Workstation 2.0 software (VIDA Diagnostics, Coralville, 
Iowa). Image registration of 3He ventilation, ADC, and CT 
images was performed using a custom algorithm in MATLAB 
R2018a software (Mathworks, Natick, Mass). CT and 1H MRI 
were nonrigidly registered using the modality-independent 
neighborhood descriptor method (32); 3He ventilation and 
Figure 1: Flowchart shows the participants enrolled in the 
study. COPD = chronic obstructive pulmonary disease, mPRM = 
multiparametric response map.
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perinflation and small airways disease, respectively. Figure 5, 
B, also shows there was a greater fraction of abnormal mPRM 
voxels as COPD severity increased.
mPRM Relationships with Pulmonary Measurements
Table 2 shows Spearman correlation coefficients for mPRM 
lung fraction measurements with FEV1 percentage pre-
dicted, FEV1-to-forced vital capacity (FVC) ratio (hereafter, 
FEV1/FVC), DLco, SGRQ total score, and 6-minute walk 
distance in ex-smokers with or without COPD. In all par-
ticipants, normal mPRM lung fraction measurements (green 
voxels in Figs 3, 5) were correlated with FEV1 percentage 
predicted (r = 0.65, P , .001), FEV1/FVC (r = 0.81, P , 
.001), DLco (r = 0.75, P , .001), and SGRQ (r = 20.48, 
P , .001). The mPRM ventilated, normal CT, and abnormal 
ADC (yellow voxels) lung fraction measurements were corre-
lated with FEV1 percentage predicted (r = 20.42, P , .001), 
FEV1/FVC (r = 20.60, P , .001), DLco (r = 20.60, P , 
.001), and SGRQ (r = 0.33, P , .001). Table 2 also shows that 
mPRM ventilated, CT emphysema, and abnormal ADC (or-
ange voxels) lung fraction measurements were correlated with 
FEV1 percentage predicted (r = 20.64, P , .001), FEV1/FVC 
(r = 20.83, P , .001), DLco (r = 20.66, P , .001), and 
SGRQ (r = 0.45, P , .001). Unventilated with normal CT 
(red voxels in Figs 3, 5) mPRM lung fraction measurements 
were correlated with FEV1 percentage predicted (r = 20.65, 
P , .001), FEV1/FVC (r = 20.70, P , .001), DLco (r = 20.53, 
P , .001), and SGRQ (r = 0.45, P , .001) (Figs 3, 5), whereas 
unventilated CT emphysema (burgundy voxels) lung fraction 
Results
Study Participants
Participants were aged 48–87 
years (mean age, 69 years 6 
9 [standard deviation]; mean 
age of men, 70 years 6 10; 
age range of men, 48–87 years; 
mean age of women, 68 years 
6 8; age range of women, 
52–83 years). We generated 
mPRM measurements (Figs 2, 
3) in 175 ex-smokers without 
(n = 67; mean age, 68 years 6 
10; 39 men) or with Global 
initiative for chronic Obstruc-
tive Lung Disease (GOLD) 
grade I (n = 24; mean age, 74 
years 6 7; 20 men), grade II 
(n = 49; mean age, 69 years 6 
8; 29 men), or grade III/IV (n 
= 35; mean age, 68 years 6 9; 
20 men) COPD. Mean ADC 
in the participants who never 
smoked was 0.26 cm2/sec 6 
0.04, which was consistent 
with previous work (35) and 
was used to determine the ab-
normal ADC threshold. Figure 1 shows that of the 263 total 
participants enrolled, 53 withdrew prior to the first visit; 10 
had bronchiectasis, not COPD; and 25 did not complete imag-
ing (either MRI or CT); thus, 175 participants were evaluated.
Table 1 provides participant characteristics, pulmonary 
function test results, and imaging and quality-of-life mea-
surements for all participants and for participants classified 
by subgroup according to GOLD criteria, which were dif-
ferent across subgroups (all P  .05). Figure 4 shows repre-
sentative 3He ventilation MRI scans, as well as ADC and CT 
maps showing relative area of the lung with attenuation less 
than 2950 HU. Figure 4 also shows there was qualitatively 
worse or increased MRI ventilation heterogeneity, ADC, and 
voxels with attenuation less than 2950 HU with increasing 
COPD severity.
mPRM Lung Fraction Measurements
Figure 5 shows the resultant mPRM findings for all participants 
by lung fraction and representative center-slice coronal mPRM 
maps for representative participants who were ex-smokers with 
or without COPD. Figure 5, A, shows there was a larger frac-
tion of normal mPRM voxels in ex-smokers (all P  .001) and 
a smaller fraction of abnormal mPRM voxels compared with 
all subgroups of participants with COPD. Ex-smokers without 
COPD also reported a smaller fraction of unventilated normal 
CT voxels compared with ex-smokers with GOLD II or III/IV 
COPD (all P , .001). The mPRM analysis revealed two novel 
mPRM voxel types, both of which were present in otherwise 
healthy ex-smokers, and which reflect mild emphysema or hy-
Figure 2: Multiparametric response map thresholds and decision tree. ADC = apparent diffusion coefficient.
MacNeil et al
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ventilation, CT, and ADC; (b) normal ventilation and CT 
but abnormal ADC; and (c) nonventilated and normal CT. 
For example, Figure 6, A, shows a resultant or normal mPRM 
map in a 51-year-old man with a 32 pack-year smoking his-
tory, normal spirometry results (FEV1 = 75% predicted, 
FEV1/FVC = 0.77), and normal DLco (95% predicted). In 
contrast, in Figure 6, B, there is a mixture of (a) normal 
ventilation, CT, and ADC and (b) normal ventilation and 
CT but abnormal ADC in a 76-year-old man with a 24 
pack-year smoking history, normal spirometry results (FEV1 = 
115% predicted, FEV1/FVC = 0.72), and abnormal DLco 
(59% predicted). Figure 6, C, is an mPRM map obtained 
in an 80-year-old woman with a 27 pack-year smoking his-
tory, similar pulmonary function measurements (FEV1 = 
124% predicted, FEV1/FVC = 0.71), and abnormal DLco 
measurements were correlated with FEV1 percentage predicted 
(r = 20.72, P , .001), FEV1/FVC (r = 20.86, P , .001), 
DLco (r = 20.63, P , .001), and SGRQ (r = 0.46, P , .001). 
Table 2 also shows that all mPRM lung fraction measurements 
except for ventilated, normal CT, and abnormal ADC were 
correlated with 6-minute walk distance. Figures E1–E5 (on-
line) show univariate regressions for mPRM lung fraction and 
clinical measurements, while Table E1 (online) provides Spear-
man correlation coefficients for all disease severity subgroups.
mPRM Phenotypes in Ex-Smokers without COPD
Figure 6 shows mPRMs for four representative ex-smokers 
with normal spirometry and CT results. These maps high-
light the heterogeneity observed in ex-smokers and the re-
gional distribution of mPRM voxels, including (a) normal 
Figure 3: Schematic for multiparametric (MRI and CT) response maps in the setting of chronic obstructive pulmonary disease 
(COPD). Top: Co-registration of three contemporaneously acquired images in an ex-smoker with Global initiative for chronic Ob-
structive Lung Disease III/IV COPD (CT, MRI ventilation, MRI apparent diffusion coefficient [ADC]) into one map. Bottom: Three-
dimensional multiparametric response map voxel classification. Green = ventilated voxels, CT  2950 HU, normal ADC; yellow = 
ventilated voxels, CT  2950 HU, and abnormal ADC (.0.30 cm2/sec); orange = ventilated voxels, CT emphysema, and abnor-
mal ADC; red = not ventilated, CT  2950 HU, no measurable ADC; burgundy = not ventilated, CT emphysema, no measurable 
ADC; clear = registration error.
Multiparametric Response Maps of COPD
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CT and MRI studies in participants with COPD (4,21,24,36). 
These previous studies also showed that as COPD severity in-
creased, there was a decrease in total airway count and terminal 
bronchioles (24,36). With increasing COPD severity, mPRM 
measurements also transition from (a) mainly normal voxels to 
(b) hyperinflated or mild emphysema voxels to (c) ventilation 
abnormalities and then to (d) advanced emphysema with venti-
lation abnormalities.
These mPRM lung fraction measurements were also cor-
related with pulmonary function, quality of life, and exercise 
capacity. The relationship of mPRM phenotypes with DLco 
appears to transition from potential subclinical emphysema in 
ex-smokers with normal spirometry and CT results to progres-
sively more severe emphysema in the setting of COPD. These 
results are consistent with previous findings of the strong rela-
tionship between DLco and measures of emphysema (2,3,22).
By identifying abnormal lung regions using mPRM maps, 
there is the potential to provide insight into the transition from 
normal to diseased COPD states, but this hypothesis requires 
testing in a prospective longitudinal study. The heterogeneity of 
mPRM maps in at-risk ex-smokers shows the presence of ab-
normal lung regions that are not obvious on CT or MRI scans 
alone. Voxels with normal CT and ventilation but an abnormal 
ADC can be interpreted in the context of previous work that re-
vealed MRI evidence of subclinical airspace enlargement (due to 
emphysema or alveolar distension) in a small group of ex-smok-
ers without CT maps showing relative area of the lung with at-
tenuation less than 2950 HU, consistent with emphysema (22). 
Regions of elevated ADC may indicate regions of subclinical 
(49% predicted) that consists of mainly normal ventilation 
and CT but abnormal ADC. Finally, Figure 6, D, shows 
an mPRM map in a 72-year-old man with a 20 pack-year 
smoking history and normal spirometry (FEV1 = 122% 
predicted, FEV1/FVC = 0.80) and DLco (73% predicted) 
results that consists of a mixture of normal ventilation, CT, 
and ADC throughout the lungs and nonventilated, normal 
CT, and no ADC in wedge-shaped peripheral (subsegmen-
tal) regions.
Discussion
Previous work has shown that hyperpolarized gas MRI and 
CT provide complementary disease information in the setting 
of chronic obstructive pulmonary disease (COPD), but this 
information has not been combined into one image. In this 
study, we generated multiparametric response map (mPRM) 
measurements by combining CT and MRI data in 175 ex-
smokers, including 108 participants with and 67 without 
COPD. We observed (a) significantly different mPRM lung 
fraction measurements with increasing disease severity, (b) sig-
nificant associations for mPRM lung fraction measurements 
with pulmonary function and quality of life (all P , .001), 
and (c) two mPRM voxel types that were suggestive of disease 
transition or progression in ex-smokers with normal spirom-
etry and CT results, neither of which were detected with CT 
or MRI alone.
Lung fraction measurements obtained with mPRM were 
significantly different with increasing COPD severity, which 
is not surprising given the results of previous single-modality 
Table 1: Participant Characteristics
Parameter
All  
(n = 175)
Ex-smokers without COPD  
(n = 67)
GOLD I  
(n = 24)
GOLD II  
(n = 49)
GOLD III/IV  
(n = 35)
Age (y) 69 6 9 68 6 10 74 6 7 69 6 8 68 6 9
Men* 108 (62) 39 (58) 20 (83) 29 (59) 20 (57)
BMI (kg/m2) 28 6 5 29 6 4 28 6 4 26 6 4 26 6 5
No. of pack-years 40 6 28 28 6 18 48 6 34 46 6 28 53 6 30
FEV1 (%pred) 77 6 28 98 6 19 95 6 11 64 6 9 35 6 7
FVC (%pred) 91 6 19 92 6 17 109 6 12 92 6 15 71 6 15
FEV1/FVC 0.62 6 0.18 0.80 6 0.06 0.63 6 0.05 0.53 6 0.09 0.38 6 0.08
TLC (%pred) 111 6 18 101 6 14 112 6 12 115 6 18 125 6 17
RV/TLC (%pred) 121 6 27 107 6 18 107 6 17 125 6 18 161 6 23
RAW (%pred) 170 6 140 (n = 173) 115 6 66 122 6 44 175 6 112 314 6 218 (n = 33)
DLco (%pred) 65 6 23 (n = 173) 79 6 21 69 6 19 57 6 18 (n = 48) 42 6 18 (n = 34)
RA950 (%) 6 6 9 1 6 1 4 6 4 8 6 9 16 6 11
VDP (%) 12 6 10 6 6 4 8 6 5 14 6 8 25 6 9
ADC (cm2/sec) 0.35 6 0.11 0.26 6 0.03 0.34 6 0.08 0.39 6 0.10 0.46 6 0.09
SGRQ total 35 6 22 (n = 165) 25 6 22 (n = 61) 23 6 16 (n = 22) 38 6 15 (n = 48) 58 6 13 (n = 34)
6MWD (min) 393 6 87 (n = 163) 405 6 91 (n = 65) 420 6 50 399 6 88 (n = 46) 340 6 83 (n = 28)
Note.—Unless otherwise indicated, data are mean 6 standard deviation and data in parentheses are numbers of patients. ADC = appar-
ent diffusion coefficient, BMI = body mass index, COPD = chronic obstructive pulmonary disease, DLco = diffusing capacity of the lung 
for carbon monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, GOLD = Global initiative for chronic 
Obstructive Lung Disease grade, %pred = percentage predicted, RAW = airways resistance, RA950 = relative area of the lung , 2950 HU, RV 
= residual volume, SGRQ = St George’s Respiratory Questionnaire, 6MWD = 6-minute walk distance, TLC = total lung capacity, VDP = 
ventilation defect percentage.
* Data are numbers of participants, and data in parentheses are percentages.
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pathophysiology and the finding of increasingly abnormal 
tissue and small airway structure and function in partici-
pants with more advanced or severe COPD. However, on 
the basis of previous findings, we did not expect to observe 
mPRM evidence of small airways disease (not ventilated, 
normal CT) and mild emphysema (ventilated, normal 
CT, abnormal ADC) in ex-smokers with otherwise nor-
mal CT and spirometry values. These two novel findings in 
a highly heterogeneous convenience sample of ex-smokers 
emphysema, possible al-
veolar distention, or gas 
trapping and are consis-
tent with previous find-
ings (21,22). While these 
microstructural changes 
are not visible on CT im-
ages or reflected with spi-
rometry, they may be an 
indicator of early termi-
nal airspace destruction.
Another key finding 
in otherwise healthy ex-
smokers is regions of the 
lung that have normal 
CT voxels but no gas dis-
tribution. These regions 
are consistent with sub-
segmental small airways 
disease. In the setting of 
COPD, the narrowing 
or destruction of small 
airways is thought to 
precede the development 
of emphysema (36), but 
the affected small airways 
cannot be detected with 
spirometry and are invis-
ible on CT (14,37). CT 
parametric response maps 
have also provided a way 
to regionally identify gas 
trapping based on voxels 
that appear normal on 
inspiration CT but ab-
normal (,856 HU) on 
expiration CT (4,14), 
and it has been validated 
as an imaging measure-
ment of small airways 
disease in the setting of 
very severe COPD (38). 
Multimodality mPRMs 
unite structural and func-
tional abnormalities in a 
way that resembles CT 
parametric response map 
measurements of emphy-
sema and small airways disease and may provide another way to 
highlight the transition phases in the setting of COPD. Further 
evaluation of unventilated normal CT voxels is required with 
CT airway and parametric response map measurements to clar-
ify the pathophysiology responsible for these findings.
We expected to observe overlap of structure and func-
tion imaging findings in participants with COPD. In other 
words, the mPRM findings in patients with GOLD grades I–
IV COPD are in keeping with our understanding of COPD 
Figure 4: Representative coronal MRI and CT scans by chronic obstructive pulmonary disease (COPD) severity. Ventilation 
is shown in blue. Yellow shows relative area of the lung with CT attenuation less than 2950 HU (RA950) on inspiratory CT. The 
ex-smoker without COPD was a 56-year-old man with a 41 pack-year smoking history and normal pulmonary function (forced 
expiratory volume in 1 second [FEV1] = 101%, FEV1/forced vital capacity [FVC] ratio = 0.89, residual volume [RV]/total lung ca-
pacity [TLC] ratio = 106%, diffusing capacity of the lung for carbon monoxide [DLco] = 79%; all are percentage predicted). The 
subject with Global initiative for chronic Obstructive Lung Disease (GOLD I) disease was an 87-year-old man with a 15 pack-year 
smoking history and modestly abnormal pulmonary function (FEV1 = 88%, FEV1/FVC = 0.60, RV/TLC = 95%, DLco = 59%; all are 
percentage predicted). The participant with GOLD II disease was a 77-year-old woman with a 112 pack-year smoking history 
and abnormal airflow, hyperinflation, and diffusing capacity (FEV1 = 66%, FEV1/FVC = 0.51, RV/TLC = 145%, DLco = 49%; all are 
percentage predicted). The subject with GOLD III/IV disease was a 76-year-old woman with a 30 pack-year smoking history and 
highly abnormal airflow, hyperinflation, and highly abnormal diffusing capacity (FEV1 = 37%, FEV1/FVC = 0.52, RV/TLC = 139%, 
DLco = 19%; all are percentage predicted). ADC = apparent diffusion coefficient.
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accuracy (Appendix E1 [online]). ADC images have twice the 
slice thickness compared with ventilation images, which often 
makes resampling complex. We also used a fixed threshold for 
CT emphysema (3) and an experimentally derived fixed ADC 
threshold (33) based on assumptions about ADC values in age-
matched participants who never smoked. Other factors (35,39) 
may influence ADC values in participants with relatively 
healthy lungs; therefore, the ADC threshold we used might not 
without airflow obstruction challenge our understanding of 
normal pulmonary function test results in ex-smokers who 
currently are not considered to have and are not currently un-
dergoing treatment for COPD.
We acknowledge several study limitations, including the 
fact that MRI and CT co-registration errors will influence voxel 
classification. Importantly, CT and MRI scans were acquired 
at the same lung volume, assisting with image registration 
Figure 5: Multiparametric response map (mPRM) lung fraction measurements and increasing chronic obstructive pulmonary disease 
(COPD) severity. A, The mPRM voxel category by lung fraction for all ex-smokers without COPD (n = 67) and those with Global initiative for 
chronic Obstructive Lung Disease (GOLD) grade I (n = 24), II (n = 49), or III/IV (n = 35) disease. In ex-smokers with no spirometric evidence 
of COPD, there is a larger fraction of normal voxels and a smaller fraction of abnormal voxels than in COPD subgroups. As COPD grade 
increases, there is a decrease in the number of normal voxels and an increase in the number of abnormal voxels. B, Representative mPRM 
voxel maps in a 79-year-old ex-smoker (32 pack-year smoking history) without COPD (mainly green [normal] and yellow [ventilated, CT 
 2950 HU, abnormal apparent diffusion coefficient {ADC}] voxels) and participants with GOLD grade I (71-year-old participant, 66 
pack-year smoking history) (mainly yellow, orange [ventilated, CT emphysema, abnormal ADC], and red [not ventilated, CT  2950 HU] 
voxels), GOLD grade II (86-year-old participant, 50 pack-year smoking history) (similar to GOLD I except with a greater amount of orange 
and red voxels), and GOLD grade III/IV (68-year-old participant, 93 pack-year smoking history) (similar to GOLD II except with greater 
amounts of burgundy [not ventilated, CT emphysema] voxels) disease. * P  .001 compared with ex-smokers without COPD. ** indicates P 
, .01 compared with GOLD I.
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the lack of progression (or on the progression) of these two 
new imaging phenotypes of COPD remains to be investigated.
In conclusion, we developed a multimodality image process-
ing pipeline to generate pulmonary multiparametric response 
map measurements that were related to pulmonary function 
tests and quality of life and that revealed phenotypes in at-risk 
ex-smokers that were not detected with CT or MRI alone. To 
our knowledge, this is the first multiparametric analysis of tho-
racic CT and MRI in patients with chronic obstructive pulmo-
nary disease and at-risk ex-smokers.
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represent terminal airspace enlargement or emphysema but in-
stead airspace distention. We acquired CT images at functional 
residual capacity + 1 L instead of at full inspiration, for which 
the 2950-HU threshold is validated (3). For the participants 
in our study and on the basis of plethysmographic data, func-
tional residual capacity + 1 L is equal to 80%–90% of total 
lung capacity, especially when the participant is lying supine in 
the scanner. This means that the estimates of CT emphysema 
here should be considered fractionally lower than estimates for 
patients at full inflation, but this difference is unlikely to be 
clinically relevant (34). Nevertheless, the emphysema estimates 
in participants in our study are similar to those in other pub-
lished studies, such as Multi-Ethnic Study of Atherosclerosis, 
or MESA (9), Canadian Cohort Obstructive Lung Disease, or 
CANCold (40), Subpopulations and Intermediate Outcome 
Measures in COPD, or SPIROMICS (5), and Genetic Epide-
miology of Chronic Obstructive Pulmonary Disease, or COP-
DGene (41). Another limitation of this study was the lack of a 
control group of age-matched participants who never smoked, 
which would help provide a better understanding of the physi-
ologic relevance of the mPRM values. Longitudinal data on 
Table 2: Spearman Correlation Coefficients for mPRM Voxel Classes as a Fraction of Total Lung
Spearman Correlation  
Coefficient (r)
Normal  
(% of lung)
Ventilated +  
CT  2950 HU+  
Abnormal ADC (% of lung)
Ventilated + CT  
Emphysema + Abnormal  
ADC (% of lung)
Not Ventilated +  
CT  2950 HU +  
No ADC (% of lung)
Not Ventilated + CT 
Emphysema + No  
ADC (% of lung)
FEV1 (%pred) 0.65 (,.001)* 20.42 (,.001)* 20.64 (,.001)* 20.65 (,.001)* 20.72 (,.001)*
FEV1/FVC 0.81 (,.001)* 20.60 (,.001)* 20.83 (,.001)* 20.70 (,.001)* 20.86 (,.001)*
DLco (%pred) (n = 173) 0.75 (,.001)* 20.60 (,.001)* 20.66 (,.001)* 20.53 (,.001)* 20.63 (,.001)*
SGRQ (n = 165) 20.48 (,.001)* 0.33 (,.001)* 0.45 (,.001)* 0.45 (,.001)* 0.46 (,.001)*
6MWD (n = 163) 0.28 (.002)* 20.19 (.08) 20.27 (.003)* 20.29 (.001)* 20.29 (.001)*
Note.—Data in parentheses are P values and were adjusted using Bonferroni correction of six to account for multiple comparisons for mul-
tiparametric response map (mPRM) voxel classes. ADC = apparent diffusion coefficient, DLco = diffusing capacity of the lung for carbon 
monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, %pred = percentage predicted, 6MWD = 6-minute 
walk distance, SGRQ = St George’s Respiratory Questionnaire total score.
* Correlations are significant.
Figure 6: Multiparametric response maps (mPRMs) in representative ex-smokers without chronic obstructive pulmonary disease 
(COPD). A, Mainly green (normal) voxels in a 51-year-old man (32 pack-year smoking history, forced expiratory volume in 1  
second [FEV1] = 75%, FEV1/forced vital capacity [FVC] = 0.77, diffusing capacity of the lung for carbon monoxide[ DLco] = 95%). 
B, Mixture of green (normal) and yellow (ventilated, CT  2950 HU, abnormal apparent diffusion coefficient [ADC]) voxels in a  
76-year-old man (24 pack-year smoking history, FEV1 = 115%, FEV1/FVC = 0.72, DLco = 59%). C, Mainly yellow (ventilated,  
CT  2950 HU, abnormal ADC) voxels in an 80-year-old woman (27 pack-year smoking history, FEV1 = 124%, FEV1/FVC = 
0.71, DLco = 49%). D, Mixture of green (normal), yellow (ventilated, CT  2950 HU, abnormal ADC), and red (not ventilated,  
CT  2950 HU) voxels in a 72-year-old man (20 pack-year smoking history, FEV1 = 122%, FEV1/FVC = 0.80, DLco = 73%).  
All percentages are percentage predicted.
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